Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series

Atezolizumab plus bevacizumab is the recommended first-line treatment for unresectable hepatocellular carcinoma, based on guidelines from the Barcelona Clinic Liver Cancer prognosis and treatment strategy. However, atezolizumab plus bevacizumab may be used after administration of lenvatinib. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichimura, Takenori, Ichikura, Daisuke, Hinata, Miwa, Hida, Noriko, Baba, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064459/
https://www.ncbi.nlm.nih.gov/pubmed/37009547
http://dx.doi.org/10.1177/2050313X231164488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064459/
https://www.ncbi.nlm.nih.gov/pubmed/37009547
http://dx.doi.org/10.1177/2050313X231164488

Ejemplares similares